title: [Hepatitis C: from pathogenesis to treatment].
abstract: Hepatitis C virus (HCV) belongs to the greater family of Flaviviridae. It is probably responsible for the majority of NANB hepatitis. Serologic evidence in the term of antibodies against certain parts of HCV persists in 60 to 100% of patients with NANB hepatitis after blood transfusion. The evidence for the existence of a second virus responsible for NANB has not been excluded as inactivation-studies would suggest. HCV is also a common cause for sporadic acute hepatitis. It is the purpose of this article to present diagnosis, course and treatment of this form of hepatitis.
authors.affiliation: Hôpital du Samaritain, Vevey.
authors.forename: J
authors.initials: J
authors.lastname: Delarive
authors.forename: J P
authors.initials: JP
authors.lastname: Berger
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D018937:Hepatitis C Antibodies; D006521:Hepatitis, Chronic / Q000209:etiology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008113:Liver Neoplasms / Q000209:etiology
chemical_list: D000998:Antiviral Agents; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D007372:Interferons